A high prevalence of arterial hypertension in patients with mitochondrial diseases
Caroline Chong-Nguyen
Cardiology Department, AP-HP, Cochin Hospital, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris, France
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorCaroline Stalens
Paris Cardiovascular Research Centre (Inserm U970), Paris, France
Medical Affairs Department, AFM-Telethon, Paris, France
Search for more papers by this authorYves Goursot
Cardiology Department, AP-HP, Cochin Hospital, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris, France
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorWulfran Bougouin
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
Medical Intensive Care Unit, AP-HP, Cochin Hospital, Paris, France
Paris Cardiovascular Research Centre (PARCC), INSERM Unit 970, Paris, France
Search for more papers by this authorTanya Stojkovic
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorAnthony Béhin
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorFanny Mochel
Pierre et Marie Curie-Paris 6 University, Myology Institute, Pitié-Salpêtrière Hospital, Paris, France
Genetics Department, INSERM UMR S975, CNRS UMR7225, ICM, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
Search for more papers by this authorNawal Berber
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorBruno Eymard
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Pierre et Marie Curie-Paris 6 University, Myology Institute, Pitié-Salpêtrière Hospital, Paris, France
Search for more papers by this authorDenis Duboc
Cardiology Department, AP-HP, Cochin Hospital, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris, France
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris, France
Search for more papers by this authorPascal Laforêt
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Pierre et Marie Curie-Paris 6 University, Myology Institute, Pitié-Salpêtrière Hospital, Paris, France
Search for more papers by this authorCorresponding Author
Karim Wahbi
Cardiology Department, AP-HP, Cochin Hospital, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris, France
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris, France
Correspondence
Karim Wahbi, Cardiology Department, Cochin Hospital, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France.
Email: [email protected]
Search for more papers by this authorCaroline Chong-Nguyen
Cardiology Department, AP-HP, Cochin Hospital, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris, France
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorCaroline Stalens
Paris Cardiovascular Research Centre (Inserm U970), Paris, France
Medical Affairs Department, AFM-Telethon, Paris, France
Search for more papers by this authorYves Goursot
Cardiology Department, AP-HP, Cochin Hospital, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris, France
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorWulfran Bougouin
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
Medical Intensive Care Unit, AP-HP, Cochin Hospital, Paris, France
Paris Cardiovascular Research Centre (PARCC), INSERM Unit 970, Paris, France
Search for more papers by this authorTanya Stojkovic
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorAnthony Béhin
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorFanny Mochel
Pierre et Marie Curie-Paris 6 University, Myology Institute, Pitié-Salpêtrière Hospital, Paris, France
Genetics Department, INSERM UMR S975, CNRS UMR7225, ICM, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
Search for more papers by this authorNawal Berber
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Search for more papers by this authorBruno Eymard
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Pierre et Marie Curie-Paris 6 University, Myology Institute, Pitié-Salpêtrière Hospital, Paris, France
Search for more papers by this authorDenis Duboc
Cardiology Department, AP-HP, Cochin Hospital, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris, France
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris, France
Search for more papers by this authorPascal Laforêt
AP-HP, Pitié-Salpêtrière Hospital, Reference Center for Muscle Diseases Paris-Est, Myology Institute, Paris, France
Pierre et Marie Curie-Paris 6 University, Myology Institute, Pitié-Salpêtrière Hospital, Paris, France
Search for more papers by this authorCorresponding Author
Karim Wahbi
Cardiology Department, AP-HP, Cochin Hospital, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris, France
Université Paris Descartes-Sorbonne Paris Cité, Paris, France
INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris, France
Correspondence
Karim Wahbi, Cardiology Department, Cochin Hospital, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France.
Email: [email protected]
Search for more papers by this authorAbstract
The prevalence of arterial hypertension in mitochondrial diseases remains unknown. Between January 2000 and May 2014, we retrospectively included patients with genetically proven mitochondrial diseases. We recorded clinical, genetic and cardiac exploration data, including the measure of arterial pressure. Among the 260 patients included in the study (mean age = 44 ± 15 years, women = 158), 108 (41.5%) presented with arterial hypertension. The prevalence of hypertension by sex and age was higher than that observed in the general population for all groups. The prevalence of hypertension was significantly higher in patients with MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) mutations (66%) and MERRF (myoclonus, epilepsy, ataxia with ragged ref fibres) mutations (61%). In patients with MELAS mutation, the presence of hypertension was significantly associated with age and mutation rate in the blood (odds ratio = 1.12; P = .02) in multivariate analysis. The prevalence of hypertension was more important in patients having a mitochondrial disease. The increased risk was more important in patient with MELAS or MERRF and depended on the rate of heteroplasmy.
REFERENCES
- 1Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet. 2008; 83: 254-260.
- 2DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003; 348: 2656-2668.
- 3Wahbi K, Bougouin W, Béhin A, et al. Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases. Eur Heart J. 2015; 36: 2886-2893.
- 4Tuppen HA, Blakely EL, Turnbull DM, Taylor RW. Mitochondrial DNA mutations and human disease. Biochim Biophys Acta. 2010; 1797: 113-128.
- 5Hannah-Shmouni F, Sirrs S, Mezei MM, Waters PJ, Mattman A. Increased prevalence of hypertension in young adults with high heteroplasmy levels of the MELAS m.3243A>G mutation. JIMD Rep. 2013; 12: 17-23.
- 6Yang Q, Kim SK, Sun F, et al. Maternal influence on blood pressure suggests involvement of mitochondrial DNA in the pathogenesis of hypertension: the Framingham heart study. J Hypertens. 2007; 25: 2067-2073.
- 7Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021-3104.
- 8Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009; 53: 976-981.
- 9Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015; 16(3): 233-270.
- 10Perrine AL, Lecoffre C, Blacher J, Olié V. L'hypertension artérielle en France: prévalence, traitement et contrôle en 2015 et évolution depuis 2006. Behaviour. 2018; 10: 170-179.
- 11Schwartz F, Duke A, Sun F, Cui J, Manolis A, Gavras H. Mitochondrial genome mutations in hypertensive individuals. Am J Hypertens. 2004; 17: 629-635.
- 12Yin SL, Lan C, Pei H, Zhu ZQ. Mitochondrial transfer RNA mutations and hypertension. Genet Mol Res. 2015; 14: 17692-17698.
- 13Zhu HY, Wang SW, Liu L, Li YH, Chen R, Wang L. A mitochondrial mutation A4401G is involved in the pathogenesis of left ventricular hypertrophy in Chinese hypertensives. Eur J Hum Genet. 2009; 17: 172-178.
- 14Xue L, Wang M, Li H, et al. Mitochondrial tRNA mutations in 2070 Chinese Han subjects with hypertension. Mitochondrion. 2016; 30: 208-221.
- 15Koga Y, Akita Y, Junko N, et al. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology. 2006; 66: 1766-1769.
- 16Dong JY, Qin LQ, Zhang Z, et al. Effect of oral l-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011; 162: 959-965.
- 17Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res. 2007; 100: 460-473.
- 18Chow J, Rahman J, Achermann JC, Dattani MT, Rahman S. Mitochondrial disease and endocrine dysfunction. Nat Rev Endocrinol. 2017; 13(2): 92-104.
- 19DeStefano AL, Gavras H, Heard-Costa N, et al. Maternal component in the familial aggregation of hypertension. Clin Genet. 2001; 60: 13-21.
